Bessemer Group Inc. Reduces Stake in Repligen Co. (NASDAQ:RGEN)

Bessemer Group Inc. cut its stake in Repligen Co. (NASDAQ:RGEN) by 2.5% in the fourth quarter, Holdings Channel reports. The fund owned 248,689 shares of the biotechnology company’s stock after selling 6,502 shares during the period. Bessemer Group Inc.’s holdings in Repligen were worth $35,796,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of RGEN. Signaturefd LLC increased its position in Repligen by 172.2% during the fourth quarter. Signaturefd LLC now owns 196 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 124 shares during the last quarter. Sava Infond d.o.o. purchased a new stake in shares of Repligen in the 4th quarter valued at approximately $29,000. Resources Management Corp CT ADV purchased a new stake in shares of Repligen during the 3rd quarter valued at approximately $37,000. Quarry LP lifted its holdings in Repligen by 796.7% in the third quarter. Quarry LP now owns 269 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 239 shares during the last quarter. Finally, UMB Bank n.a. lifted its holdings in Repligen by 49.1% in the fourth quarter. UMB Bank n.a. now owns 334 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 110 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Up 13.7 %

Repligen stock opened at $123.85 on Thursday. The firm has a market capitalization of $6.95 billion, a P/E ratio of -242.84, a P/E/G ratio of 4.54 and a beta of 1.27. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $102.97 and a twelve month high of $182.52. The stock’s fifty day simple moving average is $144.76 and its 200-day simple moving average is $146.63.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.41 by $0.03. The company had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a positive return on equity of 4.21% and a negative net margin of 4.64%. As a group, equities analysts expect that Repligen Co. will post 1.72 earnings per share for the current fiscal year.

Insider Activity at Repligen

In other Repligen news, Director Margaret Pax purchased 250 shares of the business’s stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $150.69 per share, for a total transaction of $37,672.50. Following the completion of the purchase, the director now directly owns 1,043 shares in the company, valued at approximately $157,169.67. This represents a 31.53 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 1.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on RGEN shares. JPMorgan Chase & Co. lifted their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Friday, February 21st. Evercore ISI started coverage on shares of Repligen in a report on Tuesday, March 18th. They issued an “in-line” rating and a $155.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $180.00 target price on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group boosted their price target on shares of Repligen from $165.00 to $170.00 and gave the company a “hold” rating in a research note on Friday, February 21st. Finally, Canaccord Genuity Group began coverage on shares of Repligen in a report on Tuesday, December 17th. They issued a “hold” rating and a $165.00 price objective on the stock. Seven equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus price target of $178.64.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.